Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 5.3% in January

Iterum Therapeutics plc (NASDAQ:ITRM) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,790,000 shares, a drop of 5.3% from the January 15th total of 1,890,000 shares. Based on an average daily trading volume, of 1,020,000 shares, the short-interest ratio is presently 1.8 days. Approximately 5.3% of the shares of the company are sold short.

Iterum Therapeutics Stock Performance

Shares of NASDAQ:ITRM opened at $1.54 on Tuesday. The firm has a market cap of $42.38 million, a price-to-earnings ratio of -0.77 and a beta of 2.28. The business has a 50-day simple moving average of $1.67 and a two-hundred day simple moving average of $1.45. Iterum Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $3.02.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lee Financial Co purchased a new position in shares of Iterum Therapeutics in the 4th quarter worth $28,000. Sanctuary Advisors LLC bought a new position in shares of Iterum Therapeutics in the 4th quarter worth approximately $35,000. XTX Topco Ltd purchased a new position in shares of Iterum Therapeutics in the third quarter worth approximately $36,000. Citadel Advisors LLC purchased a new stake in Iterum Therapeutics during the fourth quarter valued at approximately $38,000. Finally, Two Sigma Investments LP bought a new position in Iterum Therapeutics in the fourth quarter worth approximately $45,000. Institutional investors own 9.21% of the company’s stock.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.